Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Keep up with the latest headlines in dermatology from the past week, including application of AI in dermatology, exposure to forever chemicals through the skin, and more.

Derm In The News: June 23-29

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants. 

In case you missed it, this week we had news about sarecycline's efficacy in periorificial dermatitis, Health Canada's authorization of lebrikizumab for AD, the FDA's investigational new drug clearance of ENS-002 for AD, and more.

The Weekly Roundup: June 24-28

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Researchers found that the hemp derivative addressed multiple facets of acne pathophysiology and improved acne scarring overall.

Study Investigates CBD as Acne and Acne Scar Treatment

Risankizumab outperformed other biologics in real-world psoriasis treatment, achieving higher PASI 90/100 rates and patient satisfaction.

AbbVie Unveils Promising 148-Week VALUE Trial Data for Risankizumab at IFPA Conference

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

clinical

Clinical

In this episode of The Cutaneous Connection, Bradley Burnam, the founder and CEO of 

, discusses his journey in the pharmaceutical landscape: from his battle with an aggressive antimicrobial resistant infection to the beginnings of Turn, and to the current state of 

Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at 

Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.

PODCAST: From Infection to Innovation - The Turn Therapeutics Story

The aesthetics industry saw a massive boom during the COVID-19 pandemic for both invasive and non-invasive procedures. Amir Karam, M.D., San Diego, Calif., reveals what caused this increase in demand for aesthetics procedures and discusses the outlook for the future of the industry. 

The Cutaneous Connection- Episode 13: The COVID-19 Cosmetic Surgery Boom

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Dermatology Times June 2024 Recap

Dermatology Times is recapping our top expert interviews from the month of June.

Interview Intersection: Expert Interviews From June 2024

Recent research has shed light on public interest of BPO utilizing relative search volume data.

Benzoyl Peroxide Interest Plummets Post-Petition: RSV Drops from 86.19 to 22.06 in 2024, Reflecting Sustained Downward Trend

Keep up with the latest headlines in dermatology from the past week, including a first-of-its-kind study linking psoriasis and OCD, DermTech's Chapter 11 bankruptcy filing, and more.

Derm In The News: June 16-22

The US Food and Drug Administration has approved dupliumab (Dupixent; Sanofi and Regeron Phamaceuticals, Inc.) for the treatment of prurigo nodularis in adult patients.  Dermatology Times© spoke with dermatologists Amy Spizuoco, DO, FAOCD, a dual board-certified dermatologist and owner of True Dermatology in New York, New York and Christopher Bunick, MD. PhD, associate professor of dermatology, Yale Department of Dermatology, to discuss how they believes dupliumab will change the way dermatologists treat prurigo nodularis. 

: This is huge for us in the dermatology community, because patients who have prurigo nodularis suffer from extreme itching and skin lesions andup until now, we've not had anything that's super successful and effective, or FDA approved for the treatment of these conditions. Having dupilumab approved for patients with prurigo nodularis is going to change how I treat patients, because now I have something that is FDA approved and has proven efficacy and safety and tolerability for my patients, as opposed to just kind of, you know, throwing the kitchen sink at them, you know, topical steroids, light treatments, you know, things that aren't super effective and not FDA approved.

: Do you see a lot of patients that are just very frustrated with this condition?

Yes. All over our dermatology community and even in primary care and other specialties. We see tons of patients suffering from this condition, because it's extremely itchy and a lot of them affect their activities of daily living. They can't sleep, they're not concentrating at work, they are not concentrating in school. We see tons of patients suffering with this condition that haven't had good treatment that's effective and safe for them.

: Understood! Is there anything else you want to add?

: Just that I'm really excited that this medication is now going to be approved for our patients suffering with prurigo nodularis. We've seen its efficacy in patients with atopic dermatitis and other conditions in the allergy immunology world. So, it is nice to see that we have something that is approved and is effective for our patients suffering from extreme itch and skin lesions.

1. Study of Dupilumab for the Treatment of Patients with Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2). ClinicalTrials.gov identifier: NCT04202679. Updated September 28, 2022. Accessed September 28, 2022.

https://clinicaltrials.gov/ct2/show/NCT04202679?term=PRIME2&cond=Prurigo+Nodularis&draw=2&rank=

2. Study of Dupilumab for the Treatment of Patients with Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME). ClinicalTrials.gov identifier: NCT04183335. Updated February 17, 2022. Accessed September 28, 2022.

https://clinicaltrials.gov/ct2/show/NCT04183335?term=PRIME%2C+dupilumab&draw=2&rank=1

Videos

Sanofi and Regeneron’s dupliumab will provide relief to patients with extreme itch and skin lesions. 

News 

FDA Approves Dupliumab for Prurigo Nodularis  

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, talks about how to treat tinea versicolor and how to keep it from coming back. 

Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses how to treat tinea versicolor.

Pointers With Dr Portela: How to Treat Tinea Versicolor 

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, visits the La Roche-Posay Thermal Treatment Center in France to discuss beneficial eczema treatments. 

In this week’s Pointers with Dr Portela, the 208SkinDoc travels to the La Roche-Posay Thermal Treatment Center. 

Pointers With Dr Portela: 5 Treatments That Fix Eczema at the La Roche-Posay Thermal Treatment Center

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, talks about tinea versicolor.

In this week’s Pointers with Dr Portela, the 208SkinDoc talks what a “summer rash” is and prevention. 


Pointers With Portela: Tinea Versicolor

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, reads Nicki Minaj’s tweets about her pearls to achieve her skin’s complexion. By breaking down the tips 1 by 1, Portela discusses the science behind her tweets and gives his recommendations for moisturizing the skin.

In this week’s Pointers with Dr Portela, the 208SkinDoc reacts to Nicki Minaj’s tweets about skin care, diving into whether her advice is true or not, and if a dermatology would recommend her routine. 

Pointers with Dr Portela: Celebrity Skin Care Advice

At the 2022 Winter Clinical Dermatology Conference, Ted Rosen, MD, professor of dermatology at Baylor College of Medicine and chief of dermatology at the Houston VA medical center in Houston, Texas, gave the presentation, "What's Hot and New in Infectious Disease?" Here he dives into the details of infectious disease and explains what some physicians may miss.

What new treatments are coming to infectious disease? How can they be prevented and what misconceptions are affecting treatment? Learn about this and more in this video with Ted Rosen, MD.

Misconceptions, Pipeline, and Prevention of ID

Ted Rosen, MD, professor of dermatology at Baylor College of Medicine and chief of dermatology at the Houston VA medical center in Houston, Texas, explains the top points of his presentation, "What's Hot and New in Infectious Disease?" from the 2022 Winter Clinical Dermatology Conference. From ticks and scabies to COVID-19, he highlights many clinical pearls.

Ted Rosen, MD, explains the top points of his presentation, "What's Hot and New in Infectious Disease?" from the 2022 Winter Clinical Dermatology Conference. 

Conferences (Dont Use)

 What's Happening in Infectious Disease?

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho discusses how to prevent dry skin on hands. He also speaks about how to treat dry skin on hands and what products he recommends to do so.

Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Time®.

In this week’s Pointers with Dr Portela, the 208SkinDoc shares tips on prevention, treatment, and products he recommends for treating dry hands caused by wintery weather. 

Pointers With Dr Portela: How to Fix Dry Skin

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho describes the 5 main types of eczema that dermatologists commonly see. He explains how each type is different and how treatment can change based on the type and age of the patient.

In this week’s Pointers with Dr Portela, the 208SkinDoc honors the end of Eczema Awareness Month with a video explaining the skin condition. 

Pointers With Dr Portela: The 5 Types of Eczema

Adelaide Hebert, MD, chief of pediatric dermatology at the McGovern Medical School at UTHealth Houston, Texas highlights how her reasoning behind how often a child should bathe and how important emollients and moisturizers are to eczema care. 

To listen to what she had to say, watch the video below.

 Well thank you so much for joining me today. My name is Morgan Petrelli, Associate Editor with dermatology times and today I'm joined by Dr. Adelaide Hebert, Dr. Hebert if you want to introduce yourself and any of the research that you're currently conducting.

 I'm Dr. Adelaide Hebert. I work at the University of Texas Medical School in Houston, Texas. I've been chief of pediatric dermatology here for 37 years, and have been actively engaged in clinical research for the past 36 years. The research interests that I have include atopic dermatitis, psoriasis, hyperhydrosis, acne, rosacea, skin, soft tissue infections, and diaper dermatitis. We really will study almost anything that deals with skin in both pediatric and adult realms. I don't typically do IV antibiotics studies, but we're very interested in biologic therapy and the new Janus kinase (JAK) inhibitors. We do the full scope we feel of research within the adult and pediatric realm.

What about when it comes to bathing? How important is that?

Well I'm pretty flexible with my patients and parents regarding bathing. I often start before I launch into what I want them to do, I see what they're doing currently. If the parent bathes the child every day or every other day, that's fine.

I'm of the mindset to let children bathe every day I usually ask if the child enjoys playing in the bath. Most of the time the answer is yes. There's a small group of patients who don't tolerate water on their skin very well. We might diminish the number of times a child [a child bathes], but I know in our hospital with the sickest children, they do play therapy, not in a tub, but they have a little swimming pool, if you will, that they put toys in and the children pack the water and play with the toys.

So we know that water is very fresh and most children enjoy a bath. It's also a time of one on one with the parent and the child, which I think is a really wonderful bonding experience. It allows the parent to examine the skin very carefully looking for infections, looking for fissures that develop, looking for what we call hotspots, and new breakthrough areas of spongiotic dermatitis. So I think all of those opportunities are really wonderful.

What's critical though, is after bathing, the child should be patted dry, not completely dried off, and then the water of the bath trapped [into the skin] with the moisturizer, usually within 3 to 5 minutes after the bath to optimize the trapping of the water. So a bath can be a very therapeutic component of the care. I'm very flexible in that now some parents really insist on once a week bathing, and the child is doing well. I'm fine with that. There are 2 schools of thought and I try not to be rigid in that unless the child is really filthy dirty, in which case, I tend to make the suggestion for hygiene and skin safety that the child be bathed a bit more frequently.

How are emollients and moisturizers different? How do they work together to treat eczema?

I think of emollient and moisturizers as being identical. They are so critical in restoring the barrier. They're the fundamental cornerstone of all the guidelines currently available for atopic dermatitis [AD] management, [and] we really need to employ these. When children or families are impoverished, we can suggest agents that are found in the grocery store where they can use food stamps. 

We tend to use whatever will restore that barrier. It may not be optimized care, but even the most impoverished patient in general can afford something in the realm of in the emollient/ moisturizer. But again, I placed special emphasis on those moisturizers that contain ceramides, because, in my experience, they have given me the best results for the patients for whom I provide care.

 What are some key counseling points regarding emollient and moisturizers?

Most importantly, find one that the child will tolerate. I'll generally recommend 2 or 3. In our clinic, we are allowed to provide samples, which I think is beneficial because a parent, before they spend any money, can try a sample on a child to see what they tolerate. 

Sometimes it's a matter of personal preference. How does that emollient feel on the skin? How easy is it for the parent to apply that agent? We have broken skin [and] we know that skin creams which come in tubs are both cost effective and effective in repairing the barrier, but they are thicker. They're a little more work for the parents to apply. Sometimes the child will become fretful and won't tolerate that degree of rubbing over the time period required to get it to go into the skin.

Some emollients come as sprays. Some emollients come as foams and sometimes those are more tolerated by any individual patient. I'm not rigid in what the parent and the patient will use, as long as they put a moisturizer on at least twice a day because this makes such a difference. It's surprising if parents come in, and they haven't had that fundamental education, and giving them the right guidance, and the right product can make a marked difference in the child's care.

I do try to avoid lotions, because they contain more water, and they can dry the skin out. If a lotion seems to be what the patient is tolerating and the skin regimen is going well again, I’m flexible, and try to allow them to use what they are most comfortable with. All these things come into play the affordability of the product [and] the ability to access it readily. We want the parents to be able to use the regiments that we outlined for them, and not make it so complicated, that it's difficult to adhere to and difficult to do daily.

What does your office recommend for patients when it comes to over the counter products?

We use almost every product available in the over-the-counter space. We like the Eucerin Eczema Care. We use all the CeraVe products, those are easy to find and readily available. We also have patients who will use Cetaphil Restoraderm. We have some who prefer the Gold Bond products. 

There are indeed many more products that contain ceramides that I haven't mentioned. We tend to have samples of these parents will often recognize these brand names, and they feel very comfortable with them. Sometimes patients are using a product that's good but doesn't get in their ceramides. We will ask them the next time they make a purchase to consider getting the agent that contains the ceramides as we think it will enhance the regimen that they're already conducting for their child.

When would a referral to a physician for more aggressive therapies be recommended?

Well, we like to treat eczema when it's not too profound. Obviously, if the primary care physician or the nurse practitioner [NP] is not comfortable and the child is not getting better, is having recurrent infections, is not sleeping or growing, or if that eczema just seems in any way to not be able to be brought under control, we're happy to see those patients in our clinic.

I think virtually every dermatologist who cares for AD is well versed in both what current therapies are available and also, we have some emerging therapies that are extremely exciting. We are very blessed in the atopic realm that some new therapies have allowed us to bring many of these patients under better control, particularly if they're age 6 and older. Currently, I'm certainly conducting research on some oral medications in the JAK inhibitor class that I think will be a great improvement in our armamentarium. Again, many patients don't like to take shots and prefer pills, but we really must design a therapy that's going to be available for the patient while tolerated by the patient, of course covered by their insurance plan.

In this episode of DermView, Adelaide Hebert, MD, highlights both emollients and moisturizers. She also talks about bathing and how often a child should bathe if they have eczema. 

General Dermatology

Latest News